Grace C. Stroman

Grace C. Stroman

Auto-generated profile, based on publicly available information

Grace C. Stroman

Department of Pharmacology, University of North Carolina, Chapel Hill, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2024 in Cancer Discovery
Verified
Journal Article
Closed access
YXYi Xu
Yi Xu
XPXianlu Laura Peng
Xianlu Laura Peng
MEMichael P. East
Michael P. East
IMIan C. McCabe
Ian C. McCabe
GSGrace C. Stroman
Grace C. Stroman
JYJen Jen Yeh
Jen Jen Yeh
Effective therapies for pancreatic ductal adenocarcinoma (PDAC) have been largely elusive. In this study, we perform multiplexed kinase inhibitor bead mass spectrometry on 102 patient-derived xenografts derived from 14 unique primary PDACs to define the tumor-intrinsic kinome landscape. Our findings uncover three kinome subgroups making up two tumor-intrinsic kinome subtypes that we call kinotypes. The kinotypes show enrichment of different kinase classes and recapitulate previously described molecular subtypes, basal-like and classical. The kinotype characterizing basal-like tumors shows enrichment of receptor tyrosine kinases, whereas the kinotype characterizing classical tumors is enriched in understudied kinases involved in Wnt signaling and immune pathways. We validate our findings in two clinical trials and show that only patients with basal-like tumors derive significant benefit from EGFR inhibitors. Our results provide a comprehensive tumor-intrinsic kinome landscape of PDAC that strongly supports actionable kinotype-specific kinase targets and provides a roadmap for kinase inhibitor therapy in PDAC. Significance: We provide a comprehensive tumor-intrinsic kinome landscape that provides a roadmap for the use of kinase inhibitors in PDAC treatment approaches.

8 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
DMDalia Martinez-Marin
Dalia Martinez-Marin
MSMonica Sharma
Monica Sharma
JWJenna C. van Wunnik
Jenna C. van Wunnik
FMFlávia Sardela de Miranda
Flávia Sardela de Miranda
GBGeetha Priya Boligala
Geetha Priya Boligala
KPKevin Pruitt
Kevin Pruitt
Dishevelled (DVL) is a crucial component of the Wnt-signaling pathway and is vital for multiple physiological processes. Previously thought to have a classically cytoplasmic role, the discovery of DVL nuclear translocation reframed how it is viewed functionally. Although significant progress has been made in understanding the nuclear functions of DVL, further research is required to clarify its roles in transcriptional and epigenetic regulation. A key unresolved question is whether nuclear DVL1 associates with a transcription factor partner. We show here that modulation of DVL1 expression globally affects the transcriptomic landscape. Additionally, analysis of DVL1 ChIP-sequencing allowed us to map genome-wide binding sites, revealing the extensive reach of DVL1 binding. Integration of RNA-sequencing and ChIP-sequencing further revealed ETS1 as a transcription factor binding partner which targets nuclear DVL1 to specific genomic loci. These findings provide insight into the contribution of DVL1 in transcription and clarify aspects of its elusive nuclear function.

17 June 2026
Verified
Other
Open access
YXYi Xu
Yi Xu
XPXianlu Laura Peng
Xianlu Laura Peng
MEMichael P. East
Michael P. East
IMIan C. McCabe
Ian C. McCabe
GSGrace C. Stroman
Grace C. Stroman
JYJen Jen Yeh
Jen Jen Yeh
Supplementary Data Figure 1. PDX show high correlation within the same patient line across different runs compared to different patient lines on the same run. Supplementary Data Figure 2. Mouse kinase expression is not line specific and does not associate with tumor molecular subtype. Supplementary Data Figure 3. Molecular subtyping in PDX model recapitulates basal-like and classical tumor specific subtypes. Supplementary Data Figure 4. Subtype specific kinase expression is associated with gene expression in PDX tumors. Supplementary Data Figure 5. Kinase expression from patients reflects the PDAC PDX kinome. Supplementary Data Figure 6. Overall survival (OS) and treatment response of patients who received EGFR inhibitors.

17 June 2026
Verified
Other
Open access
YXYi Xu
Yi Xu
XPXianlu Laura Peng
Xianlu Laura Peng
MEMichael P. East
Michael P. East
IMIan C. McCabe
Ian C. McCabe
GSGrace C. Stroman
Grace C. Stroman
JYJen Jen Yeh
Jen Jen Yeh
Supplementary Table 7.response

17 June 2026
Verified
Other
Open access
YXYi Xu
Yi Xu
XPXianlu Laura Peng
Xianlu Laura Peng
MEMichael P. East
Michael P. East
IMIan C. McCabe
Ian C. McCabe
GSGrace C. Stroman
Grace C. Stroman
JYJen Jen Yeh
Jen Jen Yeh
Supplementary Table 6.overall_survival

17 June 2026
Verified
Other
Open access
YXYi Xu
Yi Xu
XPXianlu Laura Peng
Xianlu Laura Peng
MEMichael P. East
Michael P. East
IMIan C. McCabe
Ian C. McCabe
GSGrace C. Stroman
Grace C. Stroman
JYJen Jen Yeh
Jen Jen Yeh
Supplementary Table 3.ttest_basalclassical